Analysts Expect SpringWorks Therapeutics (NASDAQ:SWTX) to Post ($0.45) EPS

SpringWorks Therapeutics (NASDAQ:SWTX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price target of $32.50 for the company and are predicting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SpringWorks Therapeutics an industry rank of 82 out of 255 based on the ratings given to its competitors.

SWTX has been the topic of a number of recent research reports. JPMorgan Chase & Co. initiated coverage on SpringWorks Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $32.00 target price on the stock. Cowen initiated coverage on SpringWorks Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. Wedbush initiated coverage on SpringWorks Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $33.00 target price on the stock. Finally, Goldman Sachs Group initiated coverage on SpringWorks Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $37.00 target price on the stock.

In related news, major shareholder Bain Capital Life Sciences Inv acquired 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $2,700,000.00. Also, Director Stephen P. Squinto acquired 275,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, for a total transaction of $4,950,000.00.

SWTX stock opened at $18.96 on Wednesday. SpringWorks Therapeutics has a 1 year low of $17.66 and a 1 year high of $28.62.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Story: What is a capital gain?

Get a free copy of the Zacks research report on SpringWorks Therapeutics (SWTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.